Obstet Gynecol Sci Search

CLOSE


Research and publication ethics

  • HOME
  • POLICY
  • Research and publication ethics

Process for identification of and dealing with allegations of research misconduct

1. Step to prevent research misconduct

The journal adheres to the ethical guidelines for research and publication described in “Good Publication Practice Guidelines for Medical Journals” (https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=7&per_page=) and “Guidelines on Good Publication” (http://www.publicationethics.org/resources/guidelines). When journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author's idea or data, complaints against editors, and other issues, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). Editorial Board will discuss the suspected cases and reach a decision. The journal will not hesitate to publish erratum, corrigendum, clarifications, retractions, and apologies when needed.

2. COPE's guideline

The resolution process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts).

Publication Ethics

1. Authorship and contributorship

The OGS follows the recommendations for authorship by the ICMJE, 2017 (http://www.icmje.org/icmje-recommendations.pdf) and Good Publication Practice Guidelines for Medical Journals 2nd Edition (KAMJE, 2013, https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=7&per_page=). Authorship credit should be based on 1) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; 2) Drafting the work or revising it critically for important intellectual content; 3) Final approval of the version to be published; and 4) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Authors should meet conditions of 1, 2, 3, and 4. In addition, an author should be accountable for the parts of the work he or she has done and should be able to identify which co-authors are responsible for specific other parts of the work. Authors should have confidence in the integrity of the contributions of their coauthors. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged as contributors not be authors. These authorship criteria are intended to reserve the status of authorship for those who deserve credit and can take responsibility for the work. The criteria are not intended for use as a means to disqualify colleagues from authorship who otherwise meet authorship criteria by denying them the opportunity to meet criterion #2 or 3. Therefore, all individuals who meet the first criterion should have the opportunity to participate in the review, drafting, and final approval of the manuscript.

A corresponding author should be designated when there are two or more authors. The corresponding author is primarily responsible for all issues to the editor and audience.

When a large, multicenter group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. When submitting a manuscript authored by a group, the corresponding author should clearly indicate the preferred citation and identify all individual authors as well as the group name. Journals generally list other members of the group in the Acknowledgments. Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship.

Contributorship is a concept that was applied initially to original research papers and it is sometimes difficult to define for other articles. Each contributorship statement should clarify the specific contributions of individuals to planning, performing, and reporting the work described in the article, as well as identify one, or occasionally more, contributor(s) as being responsible for the overall content as guarantor(s).

2. Complaints and appeal

The policy of OGS is primarily aimed at protecting the authors, reviewers, editors, and the publisher of the journal. If not described below, the process of handling complaints and appeals follows the guidelines of the Committee of Publication Ethics available from: https://publicationethics.org/appeals

Submitters, authors, reviewers, and readers may register complaints and appeals in a variety of cases as follows: falsification, fabrication, plagiarism, duplicate publication, authorship dispute, conflict of interest, ethical treatment of animals, informed consent, bias or unfair/inappropriate competitive acts, copyright, stolen data, defamation, and legal problem. If any individuals or institutions want to inform the cases, they can send a letter via the contact page on our website: https://ogscience.org/index.php?body=contact. For the complaints or appeals, concrete data with answers to all factual questions (who, when, where, what, how, why) should be provided.

The Editor, Editorial Board, or Editorial Office is responsible for complaints and appeals. A legal consultant or ethics editor may be able to help with the decision making. The consequence of remedy depends on the type or degree of misconduct. The consequence of resolution will follow the guidelines of the Committee of Publication Ethics (COPE).

3. Conflict-of-Interest Statement

The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest include financial support from or connections to pharmaceutical companies, political pressure from interest groups, and related academic issues. In particular, all sources of funding applicable to the study should be explicitly stated. Disclose any potential conflicts of interest in the Acknowledgments section of the manuscript. Authors without conflicts of interest should also include a statement in the Acknowledgments section confirming that no such interests exist. When Editor-in-Chief or Deputy Editor submit the manuscripts, they are excluded from peer review process including the reviewer selection, evaluation, and final decision.

4. Clinical data sharing policy

This journal follows the data sharing policy described in “Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors” (https://doi.org/10.3346/jkms.2017.32.7.1051). As of July 1, 2018 manuscripts submitted to ICMJE journals that report the results of interventional clinical trials must contain a data sharing statement as described below. Clinical trials that begin enrolling participants on or after January 1, 2019 must include a data sharing plan in the trial's registration. The ICMJE's policy regarding trial registration is explained at http://www.icmje.org/recommendations/browse/publishing-and-editorial-issues/clinical-trial-registration.html. If the data sharing plan changes after registration this should be reflected in the statement submitted and published with the manuscript, and updated in the registry record. All of the authors of research articles that deal with interventional clinical trials must submit data sharing plan of example 1 to 4 in Table 1. Based on the degree of sharing plan, authors should deposit their data after deidentification and report the DOI of the data and the registered site.

Table 1.Examples of data sharing statements that fulfill these ICMJE requirements*

Element Example 1 Example 2 Example 3 Example 4
Will individual participant data be available (including data dictionaries)? Yes Yes Yes Yes
What data in particular will be shared? All individual participant data collected during the trial, after deidentification. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). Not available
What other documents will be available? Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code Study protocol, statistical analysis plan, analytic code Study protocol Not available
When will data be available (start and end dates)? Immediately following publication. No end date. Beginning at 3 months and ending at 5 years following the article publication. Beginning at 9 months and ending at 36 months following the article publication. Not available
With whom? Anyone who wishes to access the data. Researchers who provide a methodologically sound proposal. Investigators whose proposed use of the data has been approved by an independent review committee (“learned intermediary”) identified for this purpose. Not available
For what types of analyses? Any purpose To achieve aims in the approved proposal. For individual participant data meta-analysis. Not available
By what mechanism will data be made available? Data are available indefinitely at (link to be included). Proposals should be directed to xxx@yyy. To gain access, data requestors will need to sign a data access agreement. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Not available
Data are available for 5 years at a third-party website (link to be included). Information regarding submitting proposals and accessing data may be found at (link to be provided). Not available
ICMJE = International Committee of Medical Journal Editors.

5. Ethical oversight

All submitted manuscripts should be original; further, they should not be under consideration for publication by other scientific journals. Any part of the accepted manuscript may not be duplicated in any other scientific journal without the permission of the editorial board. If duplicate publication related to a paper in this journal is detected, the author(s) will be named in the journal, and the respective institute(s) of affiliation will be informed; additionally, there will be penalties for the author(s). Before reviewing, all submitted manuscripts are inspected by Similarity Check powered by iThenticate (https://www.crossref.org/services/similarity-check/), a plagiarism-screening tool. If a too high a degree of similarity score is found, the Editorial Board will do a more profound content screening.

6. Intellectual property

All published papers become the permanent property of the Korean Society of Obstetrics and Gynecology. Copyrights of all published materials are owned by the Korean Society of Obstetrics and Gynecology.

7. Post-publication discussions

The post-publication discussion is available through letter to editor. If any readers have a concern on any articles published, they can submit letter to editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through erratum, corrigendum, or retraction.

  • Journal Impact Factor 1.9
  • SCImago Journal & Country Rank
  • 2.9
    2021CiteScore
     
    57th percentile
    Powered by  Scopus
  • Cervical conization with endoCUT mode applying gastrointestinal endoscopic polypectomy technique. Obstet Gynecol Sci. 2023;66:584-586


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
POLICY
FOR CONTRIBUTORS
Editorial Office
4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea.
Tel: +82-2-2266-7238    Fax: +82-2-3445-2440    E-mail: journal@ogscience.org                

Copyright © 2024 by Korean Society of Obstetrics and Gynecology.

Developed in M2PI

Close layer
prev next